BidaskClub cut shares of Dermira (NASDAQ:DERM) from a buy rating to a hold rating in a research note published on Monday morning.

Several other research firms have also issued reports on DERM. Leerink Swann reissued an outperform rating and issued a $41.00 target price (down from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Needham & Company LLC reissued a buy rating and issued a $43.00 target price (down from $46.00) on shares of Dermira in a report on Tuesday, November 7th. Cantor Fitzgerald reissued a buy rating and issued a $45.00 target price on shares of Dermira in a report on Monday, November 6th. Guggenheim reissued a buy rating and issued a $30.00 target price on shares of Dermira in a report on Thursday, December 14th. Finally, Mizuho reduced their target price on shares of Dermira from $43.00 to $39.00 and set a buy rating for the company in a report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $42.17.

Shares of Dermira (DERM) opened at $27.96 on Monday. Dermira has a fifty-two week low of $21.35 and a fifty-two week high of $38.75. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68.

Dermira (NASDAQ:DERM) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.12) by ($0.09). Dermira had a negative return on equity of 41.22% and a negative net margin of 992.18%. equities research analysts forecast that Dermira will post -7.36 EPS for the current fiscal year.

In other Dermira news, insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $27.34, for a total transaction of $82,020.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Christopher M. Griffith sold 18,458 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total transaction of $499,288.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,258 shares of company stock valued at $935,153. Insiders own 13.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in DERM. Quantbot Technologies LP grew its holdings in Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 2,309 shares in the last quarter. Aperio Group LLC purchased a new stake in Dermira during the 4th quarter valued at approximately $213,000. SG Americas Securities LLC grew its holdings in Dermira by 47.7% during the 3rd quarter. SG Americas Securities LLC now owns 8,130 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 2,627 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Dermira by 40.9% in the second quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,803 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in shares of Dermira in the fourth quarter valued at $283,000. 95.58% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/02/08/dermira-derm-rating-lowered-to-hold-at-bidaskclub.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.